In this episode Dr. Steve Perrin, CEO at the ALS Therapy Development Institute and Dr. Fernando Vieira, CSO at ALS TDI join us to talk about Antisense Oligonucleotides (ASOs). ASOs are molecules, mostly DNA, that are specifically designed to target and suppress the expression of a specific gene. They work by binding directly to messenger RNA (mRNA) and block it from producing a specific protein.

Access all episodes of the Endpoints Podcast.

Support the show.

On this episode of the Endpoints, Dr. Steve Perrin, CEO at ALS TDI answers questions about one of the most talked about clinical trials in ALS at the moment, Brainstorm Cell Therapeutics’ NurOwn, a proposed stem-cell-based treatment.